Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Biology and clinical utility of hematopoietic stem cells
Autore:
Kirov, I; Neudorf, S;
Indirizzi:
Childrens Hosp Orange Cty, Div Oncol & Hematopoiet Stem Cell Transplantat,Orange, CA 92868 USA Childrens Hosp Orange Cty Orange CA USA 92868 lantat,Orange, CA 92868 USA
Titolo Testata:
PEDIATRIC PATHOLOGY & MOLECULAR MEDICINE
fascicolo: 4, volume: 19, anno: 2000,
pagine: 283 - 302
SICI:
1522-7952(200007/08)19:4<283:BACUOH>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
BONE-MARROW TRANSPLANTATION; COLONY-STIMULATING FACTOR; ACUTE LYMPHOBLASTIC-LEUKEMIA; EX-VIVO EXPANSION; CHILDRENS CANCER GROUP; ACUTE MYELOID-LEUKEMIA; VERSUS-HOST DISEASE; CORD-BLOOD TRANSPLANTATION; HLA-IDENTICAL SIBLINGS; PERIPHERAL-BLOOD;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
111
Recensione:
Indirizzi per estratti:
Indirizzo: Neudorf, S Childrens Hosp Orange Cty, Div Oncol & Hematopoiet Stem Cell Transplantat,455 S Main St, Orange, CA 92868 USA Childrens Hosp Orange Cty 455 S Main St Orange CA USA 92868 USA
Citazione:
I. Kirov e S. Neudorf, "Biology and clinical utility of hematopoietic stem cells", PEDIAT PATH, 19(4), 2000, pp. 283-302

Abstract

Stem cell transplantation (SCT) was developed to treat patients wit malignancies and fatal disorders of hematopoiesis. For patients with malignancies, SCT allows the use of higher doses of chemotherapy +/- radiation than recipients of conventional therapy. For patients with defects in hematopoieticcells, chemotherapy is necessary to prevent rejection of the donor stem cells. The infusion of normal hematopoietic stem cells following high-dose therapy minimizes the duration of pancytopenia and replaces defective stem cells with those from a normal donor. The first successful transplants used stem cells from HLA-matched donors. At that time, the use of stem cells from partially matched allogeneic donors was limited by the difficulty in preventing, diagnosing, and treating graft-versus-host disease (GvHD). The early success seen with leukemia and nonmalignant diseases led to the expansion of the indications for SCT and has transformed SCT from an experimental procedure performed by limited number of centers to an accepted part of the treatment of cancer. Today, successful SCTs are performed using autologous stem cells, stem cells from HLA-matched, related donors; partially matched, related donors; unrelated donors, and from related and unrelated umbilical cord blood. The successes seen with these stem cell sources are the result of several advances in transplantation biology. We now have a better understanding of the relationship between residual host immunity and rejection and have used this information to develop more immunosuppressive preparative therapies capable of preventing rejection. We have a better understanding of the relationship between T cells and GvHD and have developed more effective methods to prevent and treat severe GvHD. We also have a better understanding of stem cell physiology that has resulted in our ability to quantitate hematopoietic progenitors and identify the cytokines important in inducing stem cell proliferation in vitro and in vivo. This paper reviews the recent advances in stem cell biology andhow those advances impact on clinical stem cell transplantation.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/03/20 alle ore 10:15:32